Session Title: The significance of potassium management in CKD treatment
Organized by: AstraZeneca K.K.
Session Description:
Chronic kidney disease (CKD) is attracting significant global attention because it threatens patient health, affects a large population, and is a treatable condition. It is estimated that about 10% of the world’s population has CKD, and around 20 million people are afeected in Japan, i.e., approximately one fifth of adults.
With population aging, the number of CKD patients is expected to continue rising.
This session will focus on hyperkalemia encountered during CKD management and will examine in depth the importance of potassium management in patients with CKD, with reference to recent CKD related guidelines. We will also discuss expectations for LOKELMA (sodium zirconium cyclosilicate) as one of the therapeutic options for hyperkalemia.
Learning Objectives:
・Understand CKD management based on recent CKD related guidelines.
・Consider the clinical significance of potassium management in patients with CKD.
・Consider appropriate therapeutic options for hyperkalemia in CKD patients.
・Understand the product information and clinical trial evidence for LOKELMA (sodium zirconium cyclosilicate).
| Time | Session |
|---|---|
|
5 p.m.
6 p.m.
|
|